^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tecvayli (teclistamab-cqyv)

    i
    Other names: JNJ-64007957, JNJ 64007957, JNJ64007957, JNJ 7957, Ab-957, Ab 957, Ab957, JNJ7957
    Company:
    Genmab, J&J
    Drug class:
    CD3 agonist, BCMA inhibitor
    Related drugs:
    5d
    MajesTEC-2: A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma (clinicaltrials.gov)
    P1, N=140, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Apr 2027 --> Oct 2025
    Trial primary completion date
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • pomalidomide • Ogsiveo (nirogacestat) • Tecvayli (teclistamab-cqyv)
    5d
    TRIlogy-5: A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=700, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • ramantamig (JNJ-5322) • Tecvayli (teclistamab-cqyv)
    5d
    TEAM MDA5: Study of the Efficacy and Safety of a Bispecific Antibody, Teclistamab in Severe Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5 (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
    New P2 trial
    |
    IFIH1 (Interferon Induced With Helicase C Domain 1)
    |
    Tecvayli (teclistamab-cqyv)
    5d
    A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=40, Completed, Janssen Pharmaceutical K.K. | Active, not recruiting --> Completed
    Trial completion
    |
    Tecvayli (teclistamab-cqyv)
    5d
    MMRC Horizon One: RRMM (MMRC-099) (clinicaltrials.gov)
    P2, N=300, Active, not recruiting, Multiple Myeloma Research Consortium | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Tecvayli (teclistamab-cqyv)
    7d
    MonumenTAL-6: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (clinicaltrials.gov)
    P3, N=795, Recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2028 --> Dec 2028
    Trial completion date
    |
    lenalidomide • bortezomib • pomalidomide • Empliciti (elotuzumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • dexamethasone injection
    15d
    Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial (clinicaltrials.gov)
    P2, N=74, Not yet recruiting, National Cancer Institute (NCI)
    New P2 trial
    |
    lenalidomide • carfilzomib • melphalan • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Tecvayli (teclistamab-cqyv) • Hemady (dexamethasone tablets) • plerixafor
    28d
    MASTER-2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (clinicaltrials.gov)
    P2, N=300, Recruiting, University of Alabama at Birmingham | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • melphalan • Tecvayli (teclistamab-cqyv)
    28d
    Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=26, Recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2026 --> Dec 2026 | Trial primary completion date: Sep 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Tecvayli (teclistamab-cqyv) • iberdomide (CC-220)
    1m
    GEM-TECTAL: Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, PETHEMA Foundation | Trial primary completion date: Mar 2025 --> Mar 2026
    Trial primary completion date
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    1m
    MonumenTAL-6: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (clinicaltrials.gov)
    P3, N=795, Recruiting, Janssen Research & Development, LLC | N=468 --> 795
    Enrollment change
    |
    lenalidomide • bortezomib • pomalidomide • Empliciti (elotuzumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • dexamethasone injection
    1m
    Teclistamab-Induced Localized Pleural Cavity Cytokine Release Syndrome in a Multiple Myeloma Patient Managed with Intrapleural Dexamethasone Administration. (PubMed, J Blood Med)
    She initially presented with grade 3 systemic CRS during step-up dosing phase, which partially resolved with intravenous methylprednisolone. At two months, the patient achieved a partial response and continued teclistamab therapy. To our knowledge, this is among the first reported cases of teclistamab-associated localized pleural cavity CRS effectively managed with intrapleural dexamethasone.
    Journal
    |
    IL6 (Interleukin 6)
    |
    Tecvayli (teclistamab-cqyv) • methylprednisolone sodium succinate